First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours
← catalyst calendarNCT06795022 · readout in 314 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
304estimated
Sites
21
Countries
China, Hong Kong, Japan +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-03-27 | actual | When the study began enrolling |
| Primary completion | 2027-06-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-06-30 | estimated | The whole study's end, after follow-up |
| First posted | 2025-01-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hepatocellular Carcinoma
Interventions
- Drug: AZD9793 Intravenous (IV) monotherapy
- Drug: AZD9793 Subcutaneous (SC) monotherapy
Primary outcomes
what the primary-completion date above is the date OFThe number of patients with adverse events
measured From first dose of study drug up to 30 days post last dose and prior to start of subsequent anticancer therapy
The number of patients with serious adverse events
measured From first dose of study drug up to 30 days post last dose and prior to start of subsequent anticancer therapy
The number of patients with adverse events of special interest
measured From first dose of study drug up to 30 days post last dose and prior to start of subsequent anticancer therapy
The number of AEs leading to discontinuation of AZD9793
measured From first dose of study drug up to 30 days post last dose and prior to start of subsequent anticancer therapy
The number of patients with dose-limiting toxicity (DLT), as defined in the protocol [Part A Dose Escalation only]
measured From date of first dose of study drug until the end of DLT evaluation period (up to 21, 28 or 35 days depending on dose regimen)
Objective Response Rate (ORR) [Part B Dose Expansion only]
measured From first dose of study drug to progressive disease or the last evaluable assessment in the absence of disease progression whichever comes first (up to approximately 2 years)
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed